OI
ABBV icon

Oakbrook Investments’s AbbVie ABBV Stock Holding History

Oakbrook Investments’s Portfolio ABBV Stock Details ABBV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		$218K Sell
2,860
-8,702
-75% -$741K 0.56% 69
2019
Q4 		$1.02M Sell
11,562
-253,625
-96% -$21.1M 0.21% 118
2019
Q3 		$20.1M Sell
265,187
-920
-0.3% -$63.1K 1.31% 24
2019
Q2 		$19.4M Buy
266,107
+20,650
+8% +$1.62M 1.16% 23
2019
Q1 		$19.8M Buy
245,457
+226,575
+1,200% +$18.5M 1.2% 22
2018
Q4 		$1.74M Buy
18,882
+250
+1% +$22K 0.12% 131
2018
Q3 		$1.76M Sell
18,632
-2,400
-11% -$228K 0.1% 175
2018
Q2 		$1.95M Sell
21,032
-50,030
-70% -$4.89M 0.12% 123
2018
Q1 		$6.73M Sell
71,062
-6,195
-8% -$681K 0.42% 49
2017
Q4 		$7.47M Buy
77,257
+49,300
+176% +$4.65M 0.47% 45
2017
Q3 		$2.48M Buy
27,957
+9,550
+52% +$727K 0.16% 116
2017
Q2 		$1.33M Buy
18,407
+2,400
+15% +$161K 0.09% 161
2017
Q1 		$1.04M Sell
16,007
-1,050
-6% -$66K 0.07% 215
2016
Q4 		$1.07M Sell
17,057
-1,950
-10% -$119K 0.07% 221
2016
Q3 		$1.2M Sell
19,007
-3,650
-16% -$236K 0.07% 220
2016
Q2 		$1.4M Sell
22,657
-70,560
-76% -$4.3M 0.08% 214
2016
Q1 		$5.33M Sell
93,217
-2,250
-2% -$125K 0.34% 66
2015
Q4 		$5.66M Sell
95,467
-5,440
-5% -$313K 0.36% 64
2015
Q3 		$5.49M Sell
100,907
-4,350
-4% -$283K 0.36% 61
2015
Q2 		$7.07M Sell
105,257
-8,850
-8% -$578K 0.43% 56
2015
Q1 		$6.68M Sell
114,107
-4,550
-4% -$275K 0.36% 66
2014
Q4 		$7.76M Sell
118,657
-7,850
-6% -$495K 0.42% 52
2014
Q3 		$7.31M Sell
126,507
-125,790
-50% -$6.98M 0.39% 63
2014
Q2 		$14.2M Buy
252,297
+1,450
+0.6% +$76.1K 0.43% 66
2014
Q1 		$12.9M Sell
250,847
-43,500
-15% -$2.2M 0.41% 60
2013
Q4 		$15.5M Sell
294,347
-13,125
-4% -$645K 0.43% 59
2013
Q3 		$13.8M Sell
307,472
-20,250
-6% -$898K 0.4% 66
2013
Q2 		$13.5M Buy
+327,722
New +$14.3M 0.39% 65

Other funds holding ABBV

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

Oakbrook Investments's ABBV Position: Q1 2020 in Review

Oakbrook Investments reduced its AbbVie (ABBV) stake by 75% in Q1 2020, selling an estimated $741K and leaving 2,860 shares worth $218K. The position accounts for 0.56% of the portfolio, ranked #69.

Oakbrook Investments first reported a position in ABBV in Q2 2013 and has held it in 28 quarters since. The position peaked at $20.1M in Q3 2019. 2,225 funds tracked by Wall St. Rank hold ABBV as of Q1 2020.

  • Oakbrook Investments held 2,860 shares of AbbVie worth $218K as of Q1 2020.
  • Oakbrook Investments sold 8,702 AbbVie shares in Q1 2020, an estimated $741K.
  • AbbVie made up 0.56% of Oakbrook Investments's portfolio in Q1 2020, its #69 holding.
  • Oakbrook Investments first reported a position in AbbVie in Q2 2013 and has held it in 28 quarters since.
  • Oakbrook Investments's AbbVie position peaked at $20.1M in Q3 2019.
  • 2,225 funds tracked by Wall St. Rank held AbbVie as of Q1 2020.

Based on Oakbrook Investments's 13F filing for Q1 2020, filed 22 Apr 2020.